MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Quanterix Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.52 4.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.45

Max

3.5300000000000002

Pagrindiniai rodikliai

By Trading Economics

Pajamos

10M

-23M

Pardavimai

3.7M

44M

Pelno marža

-52.712

Darbuotojai

450

EBITDA

15M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+114.29% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-137M

159M

Ankstesnė atidarymo kaina

-0.62

Ankstesnė uždarymo kaina

3.52

Naujienos nuotaikos

By Acuity

33%

67%

85 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Quanterix Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-17 20:26; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026-04-17 18:15; UTC

Svarbiausios naujienos

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026-04-17 16:49; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026-04-18 01:00; UTC

Svarbiausios naujienos

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026-04-17 22:58; UTC

Uždarbis

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026-04-17 21:32; UTC

Rinkos pokalbiai

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-17 21:22; UTC

Rinkos pokalbiai

Moody's Downgrades Belgium to A1 -- Market Talk

2026-04-17 20:52; UTC

Uždarbis

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026-04-17 20:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-04-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-17 20:29; UTC

Uždarbis

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026-04-17 20:11; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026-04-17 19:34; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-04-17 19:34; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026-04-17 19:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026-04-17 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Edge Up -- Market Talk

2026-04-17 19:21; UTC

Rinkos pokalbiai

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026-04-17 19:15; UTC

Rinkos pokalbiai

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026-04-17 19:07; UTC

Rinkos pokalbiai

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026-04-17 18:57; UTC

Svarbiausios naujienos

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026-04-17 18:53; UTC

Įsigijimai, susijungimai, perėmimai

UCB 2026 Rev Guidance Unchanged

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026-04-17 18:52; UTC

Įsigijimai, susijungimai, perėmimai

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026-04-17 18:14; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026-04-17 18:00; UTC

Svarbiausios naujienos

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026-04-17 17:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026-04-17 17:26; UTC

Rinkos pokalbiai
Uždarbis

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Akcijų palyginimas

Kainos pokytis

Quanterix Corp Prognozė

Kainos tikslas

By TipRanks

114.29% į viršų

12 mėnesių prognozė

Vidutinis 7.5 USD  114.29%

Aukščiausias 8 USD

Žemiausias 7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quanterix Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.34 / 6.015Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

85 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat